The Food and Drug Administration has approved Teva’s Ajovy for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or ...
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today that the U.S. Food and ...
AJOVY® is supported by the AJOVY® Teva Support Solutions® (AJOVY® TSS) Patient Support Program. “At Teva Canada, we welcome these new provincial formulary listings that afford greater access to AJOVY® ...
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy. The ...
FINESSE is a prospective observational study for fremanezumab to evaluate effectiveness in chronic and episodic migraine patients in routine clinical practice First interim analysis of the ...
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the ...
Teva won a U.S. appeals court ruling that upheld three patents on its Ajovy migraine drug, though six other patents on the treatment were ruled invalid, according to a Bloomberg report. Eli Lilly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback